Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Teva
UBS
Express Scripts
Citi
Baxter

Generated: August 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,097,648

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,097,648 protect, and when does it expire?

Patent 8,097,648 protects HALAVEN and is included in one NDA.

This patent has forty-one patent family members in twenty-two countries.

Summary for Patent: 8,097,648
Title:Methods and compositions for use in treating cancer
Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Towle; Murray J. (Auburn, NH), Seletsky; Boris M. (Andover, MA), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:11/282,505
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,097,648

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,097,648

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932 ➤ Sign Up
Australia 2003284242 ➤ Sign Up
Australia 4573999 ➤ Sign Up
Australia 762998 ➤ Sign Up
Belgium 2011C028 ➤ Sign Up
Brazil 9911326 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Covington
Mallinckrodt
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.